Shots: Arvinas to get ~$60M including upfront, equity investments, R&D funds and $685M milestones and royalties on sales of products. Bayer to get rights for the therapies developed in collaboration […]readmore
Tags : Arvinas
Shots: Arvinas’ ARV-110 is an orally available PROTAC protein degrader used for targeting androgen receptor (AR) protein and is currently evaluated in P-I for its safety, tolerability, and PK in […]readmore